<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03253887</url>
  </required_header>
  <id_info>
    <org_study_id>55008116.8.0000.5201</org_study_id>
    <nct_id>NCT03253887</nct_id>
  </id_info>
  <brief_title>Effectiveness of Ethanol-Lock Therapy on Prevention of Short-Term CVC Infections in Pediatric Patients (E-LockPed)</brief_title>
  <acronym>E-LockPed</acronym>
  <official_title>Effectiveness of Ethanol-Lock Therapy on Prevention of Short-Term Central Venous Catheter Infections in Pediatric Patients: A Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Materno Infantil Prof. Fernando Figueira</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bellisa Caldas Lopes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thuanne Beatriz Silva Tenório</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rodrigo Melo Gallindo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Paulo Sérgio Gomes Nogueira Borges</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leslie Sue Fernandes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lara Barreto Machado</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Materno Infantil Prof. Fernando Figueira</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Central venous catheter infection is a common complication in pediatric patients, resulting
      in prolonged length of stay in hospital, requiring antibiotics, invasive procedures and
      increase morbidity and mortality. Given the repercussion of this complication, measures that
      minimize its should be stimulated. The purpose of this study is to evaluate the effects of
      intraluminal alcoholization (ethanol lock therapy) on prevention of infection of short-term
      central venous catheters in pediatric patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients was divided into two groups, where one received alcoholization (intervention
      group - GI) and the other not (comparison group - CG). Variables studied: Central
      line-associated bloodstream infection (CLABSI), etiologic agents and his characteristic of
      resistance and weakening of the catheter. To determine the association between the
      independent variable and the dependent variables, the chi-square test of association
      (Pearson) and Fisher's exact test will be used, if necessary. The Risk Ratio (RR) will be
      calculated as a relative risk measure, with its 95% confidence interval (95% CI). NNT (number
      needed to treat and get benefit) and NNH (number needed to treat and get ill) will also be
      calculated. The significance level of 5% will be adopted. The sample size calculation was
      performed in the OpenEpi version 2.3.1 program. And a long-term catheter clinical trial was
      used to calculate the sample size, which demonstrated a 9% central venous catheter infection
      frequency in the ethanol group and 37% in the control group, so that the sample size Was 80
      patients (40 in each group), considering a power of 80%, an alpha error of 5% and 10% of
      post-randomization losses.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>It's a randomized controlled clinical trial.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of central-line catheter-related infections in the ethanol-lock group and comparative group</measure>
    <time_frame>Where central line (CL) was in place for &gt;2 calendar days on the date of event, with day of device placement being Day 1, and a CL was in place on the date of event or the day before.</time_frame>
    <description>According to CDC's National Healthcare Safety Network (CDC/NHSN) 2015 criteria for Central line-associated Bloodstream Infection (CLABSI) and CDC/NHSN Surveillance Definitions for Specific Types of Infections</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of side effects related to ethanol-lock therapy</measure>
    <time_frame>During the use of ethanol-lock therapy (number of events per patient)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocurrence of line breakage (polyurethane catheters) in the ethanol-lock group</measure>
    <time_frame>During the use of ethanol-lock therapy (number of events per patient)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Infection, Catheter-Related</condition>
  <condition>Central Line-associated Bloodstream Infection (CLABSI)</condition>
  <condition>Ethanol-lock</condition>
  <condition>Pediatric</condition>
  <arm_group>
    <arm_group_label>Ethanol-lock</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group received daily alcohol 70% (ethanol-lock) with intraluminal alcoholization of both lumens of the central venous catheters</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparative</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group did not receive the ethanol-lock, being only followed daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethanol-lock</intervention_name>
    <description>This group received daily alcohol 70% (ethanol-lock) with intraluminal alcoholization of both lumens of the central venous catheters within the first 24 hours of catheter implantation and continued until the catheter was withdrawn. Each lumen received ethanol-lock for two hours and during this period venous infusion of any venous fluids / medications was discontinued only in the lumen with alcohol. At the end, the ethanol was aspirated and the lumen released for use. Before and after each alcoholization a flush with 5-10 ml of 0.9% saline solution was performed. The CVC manipulations were performed according to the protocol in force in the service and recommended by the Centers for Disease Control and Prevention (CDC).</description>
    <arm_group_label>Ethanol-lock</arm_group_label>
    <other_name>Ethanol 70%</other_name>
    <other_name>Alcohol 70%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pediatric surgery patients;

          -  Weight: 2 Kg or more;

          -  Using of a double-lumen short-term central venous catheter (CVC);

          -  CVC realized at operation room, Pediatric Intensive Care Unit (PICU) or Neonatal
             Intensive Care Unit (NICU);

          -  CVC adequately positioned (checked by radioscopy ou radiography);

          -  CVC implanted within a maximum of 24 hours.

        Exclusion Criteria:

          -  Patients whose implantation of the catheter won't comply with all antisepsis and
             asepsis techniques determined by the study;

          -  History of hypersensitivity, reaction or allergy to ethanol;

          -  Critically ill patients requiring uninterrupted use of both catheter lumens for
             infusion of venous therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bellisa C Lopes, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Medicina Integral Prof Fernando Figueira</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bellisa C Lopes, Master</last_name>
    <phone>+55 81982501205</phone>
    <email>bellisacaldas@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Flavia Orange, PhD</last_name>
    <phone>+55 81994197979</phone>
    <email>orangeflavia@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto de Medicina Integral Prof Fernando Figueira</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <zip>50070-550</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flávia A Orange, PhD</last_name>
      <phone>+55 81 994197979</phone>
      <email>orangeflavia@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Bellisa C Lopes, Master</last_name>
      <phone>+55 81 982501205</phone>
      <email>bellisacaldas@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Bellisa C Lopes, Mastere</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thuanne BS Tenório, Graduating</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rodrigo M Gallindo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paulo GN Borges, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Flynn PM. Diagnosis and management of central venous catheter-related bloodstream infections in pediatric patients. Pediatr Infect Dis J. 2009 Nov;28(11):1016-7. doi: 10.1097/INF.0b013e3181bf7bfc. Review.</citation>
    <PMID>19859018</PMID>
  </reference>
  <reference>
    <citation>Ullman AJ, Cooke ML, Mitchell M, Lin F, New K, Long DA, Mihala G, Rickard CM. Dressings and securement devices for central venous catheters (CVC). Cochrane Database Syst Rev. 2015 Sep 10;(9):CD010367. doi: 10.1002/14651858.CD010367.pub2. Review.</citation>
    <PMID>26358142</PMID>
  </reference>
  <reference>
    <citation>Rosado V, Romanelli RM, Camargos PA. Risk factors and preventive measures for catheter-related bloodstream infections. J Pediatr (Rio J). 2011 Nov-Dec;87(6):469-77. doi: doi:10.2223/JPED.2134. Review.</citation>
    <PMID>22170387</PMID>
  </reference>
  <reference>
    <citation>Subha Rao SD, Joseph MP, Lavi R, Macaden R. Infections related to vascular catheters in a pediatric intensive care unit. Indian Pediatr. 2005 Jul;42(7):667-72.</citation>
    <PMID>16085967</PMID>
  </reference>
  <reference>
    <citation>Cruzeiro PC, Camargos PA, Miranda ME. Central venous catheter placement in children: a prospective study of complications in a Brazilian public hospital. Pediatr Surg Int. 2006 Jun;22(6):536-40. Epub 2006 May 5.</citation>
    <PMID>16736225</PMID>
  </reference>
  <reference>
    <citation>Huang EY, Chen C, Abdullah F, Aspelund G, Barnhart DC, Calkins CM, Cowles RA, Downard CD, Goldin AB, Lee SL, St Peter SD, Arca MJ; 2011 American Pediatric Surgical Association Outcomes and Clinical Trials Committee. Strategies for the prevention of central venous catheter infections: an American Pediatric Surgical Association Outcomes and Clinical Trials Committee systematic review. J Pediatr Surg. 2011 Oct;46(10):2000-11. doi: 10.1016/j.jpedsurg.2011.06.017. Review.</citation>
    <PMID>22008341</PMID>
  </reference>
  <reference>
    <citation>Webster J, Gillies D, O'Riordan E, Sherriff KL, Rickard CM. WITHDRAWN: Gauze and tape and transparent polyurethane dressings for central venous catheters. Cochrane Database Syst Rev. 2016 May 4;(5):CD003827. doi: 10.1002/14651858.CD003827.pub3. Review.</citation>
    <PMID>27144903</PMID>
  </reference>
  <reference>
    <citation>Costello JM, Morrow DF, Graham DA, Potter-Bynoe G, Sandora TJ, Laussen PC. Systematic intervention to reduce central line-associated bloodstream infection rates in a pediatric cardiac intensive care unit. Pediatrics. 2008 May;121(5):915-23. doi: 10.1542/peds.2007-1577.</citation>
    <PMID>18450894</PMID>
  </reference>
  <reference>
    <citation>Wolf J, Shenep JL, Clifford V, Curtis N, Flynn PM. Ethanol lock therapy in pediatric hematology and oncology. Pediatr Blood Cancer. 2013 Jan;60(1):18-25. doi: 10.1002/pbc.24249. Epub 2012 Aug 21. Review.</citation>
    <PMID>22911535</PMID>
  </reference>
  <reference>
    <citation>Shenep LE, Shenep MA, Cheatham W, Hoffman JM, Hale A, Williams BF, Perkins R, Hewitt CB, Hayden RT, Shenep JL. Efficacy of intravascular catheter lock solutions containing preservatives in the prevention of microbial colonization. J Hosp Infect. 2011 Dec;79(4):317-22. doi: 10.1016/j.jhin.2011.07.010. Epub 2011 Sep 25.</citation>
    <PMID>21945067</PMID>
  </reference>
  <reference>
    <citation>Wales PW, Kosar C, Carricato M, de Silva N, Lang K, Avitzur Y. Ethanol lock therapy to reduce the incidence of catheter-related bloodstream infections in home parenteral nutrition patients with intestinal failure: preliminary experience. J Pediatr Surg. 2011 May;46(5):951-6. doi: 10.1016/j.jpedsurg.2011.02.036.</citation>
    <PMID>21616259</PMID>
  </reference>
  <reference>
    <citation>Sanders J, Pithie A, Ganly P, Surgenor L, Wilson R, Merriman E, Loudon G, Judkins R, Chambers S. A prospective double-blind randomized trial comparing intraluminal ethanol with heparinized saline for the prevention of catheter-associated bloodstream infection in immunosuppressed haematology patients. J Antimicrob Chemother. 2008 Oct;62(4):809-15. doi: 10.1093/jac/dkn284. Epub 2008 Jul 11.</citation>
    <PMID>18621987</PMID>
  </reference>
  <reference>
    <citation>Chambers ST, Peddie B, Pithie A. Ethanol disinfection of plastic-adherent micro-organisms. J Hosp Infect. 2006 Jun;63(2):193-6. Epub 2006 Apr 4.</citation>
    <PMID>16600429</PMID>
  </reference>
  <reference>
    <citation>Abu-El-Haija M, Schultz J, Rahhal RM. Effects of 70% ethanol locks on rates of central line infection, thrombosis, breakage, and replacement in pediatric intestinal failure. J Pediatr Gastroenterol Nutr. 2014 Jun;58(6):703-8. doi: 10.1097/MPG.0000000000000354.</citation>
    <PMID>24590214</PMID>
  </reference>
  <reference>
    <citation>Crnich CJ, Halfmann JA, Crone WC, Maki DG. The effects of prolonged ethanol exposure on the mechanical properties of polyurethane and silicone catheters used for intravascular access. Infect Control Hosp Epidemiol. 2005 Aug;26(8):708-14.</citation>
    <PMID>16156328</PMID>
  </reference>
  <reference>
    <citation>Opilla MT, Kirby DF, Edmond MB. Use of ethanol lock therapy to reduce the incidence of catheter-related bloodstream infections in home parenteral nutrition patients. JPEN J Parenter Enteral Nutr. 2007 Jul-Aug;31(4):302-5.</citation>
    <PMID>17595439</PMID>
  </reference>
  <reference>
    <citation>Chhim RF, Crill CM, Collier HK, Arnold SR, Pourcyrous M, Meibohm B, Christensen M. Ethanol lock therapy: a pilot infusion study in infants. Ann Pharmacother. 2015 Apr;49(4):431-6. doi: 10.1177/1060028015569881. Epub 2015 Jan 28.</citation>
    <PMID>25632063</PMID>
  </reference>
  <reference>
    <citation>Upadhyayula S, Kambalapalli M, Harrison CJ. Safety of anti-infective agents for skin preparation in premature infants. Arch Dis Child. 2007 Jul;92(7):646-7. Review.</citation>
    <PMID>17588981</PMID>
  </reference>
  <reference>
    <citation>Mermel LA, Alang N. Adverse effects associated with ethanol catheter lock solutions: a systematic review. J Antimicrob Chemother. 2014 Oct;69(10):2611-9. doi: 10.1093/jac/dku182. Epub 2014 Jun 2. Review.</citation>
    <PMID>24891431</PMID>
  </reference>
  <reference>
    <citation>Sharma V, Sharma A, Kumar V, Aggarwal S. Disulfiram-like reaction with ornidazole. J Postgrad Med. 2009 Oct-Dec;55(4):292-3. doi: 10.4103/0022-3859.58940.</citation>
    <PMID>20083883</PMID>
  </reference>
  <reference>
    <citation>Karamanakos PN, Pappas P, Boumba VA, Thomas C, Malamas M, Vougiouklakis T, Marselos M. Pharmaceutical agents known to produce disulfiram-like reaction: effects on hepatic ethanol metabolism and brain monoamines. Int J Toxicol. 2007 Sep-Oct;26(5):423-32.</citation>
    <PMID>17963129</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2017</study_first_submitted>
  <study_first_submitted_qc>August 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2017</study_first_posted>
  <last_update_submitted>August 15, 2017</last_update_submitted>
  <last_update_submitted_qc>August 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Materno Infantil Prof. Fernando Figueira</investigator_affiliation>
    <investigator_full_name>Flavia orange</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Ethanol lock therapy</keyword>
  <keyword>Pediatrics</keyword>
  <keyword>Central Venous Catheter</keyword>
  <keyword>Bloodstream Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Catheter-Related Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.cdc.gov/hicpac/bsi/bsi-guidelines-2011.html</doc_url>
      <doc_comment>Guidelines for the Prevention of Intravascular Catheter-Related Infections, 2011</doc_comment>
    </study_doc>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf</doc_url>
      <doc_comment>Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and non-central line-associated Bloodstream Infection)</doc_comment>
    </study_doc>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf</doc_url>
      <doc_comment>CDC/NHSN Surveillance Definitions for Specific Types of Infections</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

